$BDSI $ENDP Biodelivery Sciences (NASDAQ: BDSI),
Post# of 2218
(Total Views: 166)
Posted On: 05/05/2017 2:58:49 PM
$BDSI $ENDP Biodelivery Sciences (NASDAQ: BDSI), a small biopharma concern with two primary pain management compounds on the market, BUNAVAIL and BELBUCA. The company had a tough 2016 as sales growth failed to meet investors’ expectations. The stock was cut in half to just under $2.00 a share. However, things should change in a couple of major ways in 2017.
First, the company signed a half-dozen agreements with insurance providers in the back half of 2016 which will greatly expand its network coverage for BUNAVAIL as those contracts have now kicked in. The company also took back BELBUCA from its marketing and distribution partner, Endo International (NASDAQ:ENDP) for minor concessions.
Endo disbanded its pain management sales force which impacted sales of several compounds from numerous companies. Overall sales of BELBUCA will probably take a hit for a few quarters as Biodelivery integrates this product into its own salesforce and adds some representatives. However, instead of just getting royalties, the company now owns the entire revenue stream from BELBUCA.
Last week, management stated on a call with analysts that it now expected to be profitable by the end of the first quarter of 2017 instead of the year, which was its previous guidance. The current analyst median price target is more than twice the shares current trading level.
Retail has been full of landmines recently
First, the company signed a half-dozen agreements with insurance providers in the back half of 2016 which will greatly expand its network coverage for BUNAVAIL as those contracts have now kicked in. The company also took back BELBUCA from its marketing and distribution partner, Endo International (NASDAQ:ENDP) for minor concessions.
Endo disbanded its pain management sales force which impacted sales of several compounds from numerous companies. Overall sales of BELBUCA will probably take a hit for a few quarters as Biodelivery integrates this product into its own salesforce and adds some representatives. However, instead of just getting royalties, the company now owns the entire revenue stream from BELBUCA.
Last week, management stated on a call with analysts that it now expected to be profitable by the end of the first quarter of 2017 instead of the year, which was its previous guidance. The current analyst median price target is more than twice the shares current trading level.
Retail has been full of landmines recently
(0)
(0)